Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19

Chloroquine (CQ) and Hydroxychloroquine (HCQ) are highly prescribed as medications for COVID-19 infection, although no robust or convincing data has yet been published about the efficacy in COVID-19 patients. Therefore, risk and benefit assessment are necessary for decision to prescribe these drugs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Jarir At Thobari
Formato:	article
Lenguaje:	EN
Publicado:	Universitas Gadjah Mada 2021
Materias:	chloroquine hydroxychloroquine covid-19 risk benefits Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/fb02e7f7df494a719045340e55b8dbab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb02e7f7df494a719045340e55b8dbab
record_format	dspace
spelling	oai:doaj.org-article:fb02e7f7df494a719045340e55b8dbab2021-11-15T06:08:46ZNarrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-192338-94272338-948610.22146/ijp.1187https://doaj.org/article/fb02e7f7df494a719045340e55b8dbab2021-08-01T00:00:00Zhttps://jurnal.ugm.ac.id/v3/IJP/article/view/1187https://doaj.org/toc/2338-9427https://doaj.org/toc/2338-9486Chloroquine (CQ) and Hydroxychloroquine (HCQ) are highly prescribed as medications for COVID-19 infection, although no robust or convincing data has yet been published about the efficacy in COVID-19 patients. Therefore, risk and benefit assessment are necessary for decision to prescribe these drugs in COVID-19 patient in hospitals settings. We systematically searched from MEDLINE Database which investigate the benefits and risks of HCQ and CQ among COVID-19 patients. All records were searched using the search terms Hydroxychloroquine, Chloroquine, COVID-19, and SARS-CoV-2. The selection criteria include all clinical trials and observational studies. We found 11 records about benefit and 7 records about risks on HCQ and CQ in COVID-19 patients after following inclusion and exclusion criteria. From clinical trial and observational studies have showed that HCQ is very limited benefit particularly on reduction of mortality or clinical improvement. Similarly, there were seven observational studies have estimated the cardiac event in use of HCQ or CQ in COVID-19. Even though no increase death, but these studies reported the increase risk of prolong QT-interval in high proportion and other cardiac events such as arrythmia, torsade de pointes and conduction block. We conclude that the benefit effect of HCQ and CQ in COVID-19 remains very limited. However, both medications have independently shown to increase the risk in other populations for QT-interval prolongation, drug-induced torsades de pointes/TDP (a form of polymorphic ventricular tachycardia) and drug-induced other cardiac events.Jarir At ThobariUniversitas Gadjah Madaarticlechloroquinehydroxychloroquinecovid-19riskbenefitsPharmacy and materia medicaRS1-441ENIndonesian Journal of Pharmacy, Pp 266-279 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chloroquine hydroxychloroquine covid-19 risk benefits Pharmacy and materia medica RS1-441
spellingShingle	chloroquine hydroxychloroquine covid-19 risk benefits Pharmacy and materia medica RS1-441 Jarir At Thobari Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
description	Chloroquine (CQ) and Hydroxychloroquine (HCQ) are highly prescribed as medications for COVID-19 infection, although no robust or convincing data has yet been published about the efficacy in COVID-19 patients. Therefore, risk and benefit assessment are necessary for decision to prescribe these drugs in COVID-19 patient in hospitals settings. We systematically searched from MEDLINE Database which investigate the benefits and risks of HCQ and CQ among COVID-19 patients. All records were searched using the search terms Hydroxychloroquine, Chloroquine, COVID-19, and SARS-CoV-2. The selection criteria include all clinical trials and observational studies. We found 11 records about benefit and 7 records about risks on HCQ and CQ in COVID-19 patients after following inclusion and exclusion criteria. From clinical trial and observational studies have showed that HCQ is very limited benefit particularly on reduction of mortality or clinical improvement. Similarly, there were seven observational studies have estimated the cardiac event in use of HCQ or CQ in COVID-19. Even though no increase death, but these studies reported the increase risk of prolong QT-interval in high proportion and other cardiac events such as arrythmia, torsade de pointes and conduction block. We conclude that the benefit effect of HCQ and CQ in COVID-19 remains very limited. However, both medications have independently shown to increase the risk in other populations for QT-interval prolongation, drug-induced torsades de pointes/TDP (a form of polymorphic ventricular tachycardia) and drug-induced other cardiac events.
format	article
author	Jarir At Thobari
author_facet	Jarir At Thobari
author_sort	Jarir At Thobari
title	Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
title_short	Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
title_full	Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
title_fullStr	Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
title_full_unstemmed	Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
title_sort	narrative review: risk-benefit hydroxychloroquine and chloroquine in covid-19
publisher	Universitas Gadjah Mada
publishDate	2021
url	https://doaj.org/article/fb02e7f7df494a719045340e55b8dbab
work_keys_str_mv	AT jariratthobari narrativereviewriskbenefithydroxychloroquineandchloroquineincovid19
_version_	1718428593934041088

Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19

Ejemplares similares